Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing 210029, China.
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing 210029, China.
Leuk Res. 2021 Jun;105:106580. doi: 10.1016/j.leukres.2021.106580. Epub 2021 Mar 29.
The study investigated serum 25-Hydroxy vitamin D (25-(OH)D) deficiency and its prognostic values of patients newly diagnosed Hodgkin lymphoma (HL). With seventy-seven patients enrolled, the median level of 25-(OH)D was 44.5 nmol/L (range, 15.5-100.9 nmol/L) and 16 (20.8 %) of them were considered as 25-(OH)D deficiency. With a median follow-up of 28 months (range, 4-56 months), the 2-year progression-free survival (PFS) and overall survival (OS) rate were 75.3 %±5.5 % and 94.7 %±3.0 %, respectively. Patients with deficient 25-(OH)D level had inferior PFS (P<0.001) as well as OS (P<0.001). In multivariate Cox analysis, 25-(OH)D deficiency was observed as an independent prognostic factor for both PFS (hazard ratio (HR) 3.323, 95 % CI 1.527-7.229, P = 0.002) and OS (HR 5.819, 95 % CI 1.322-25.622, P = 0.020). Receiver-operator characteristic (ROC) curve showed International Prognostic Score (IPS) plus 25-(OH)D deficiency (IPS-D) predicted more accurately than IPS in PFS (AUC: 0.735 (95 % CI 0.622-0.829) vs. 0.701 (95 % CI 0.586-0.800), P = 0.033) and OS (AUC: 0.864 (95 % CI 0.767-0.932) vs. 0.825 (95 % CI 0.722-0.902), P = 0.028). All these findings suggest that serum 25-(OH)D level may be an adjunctive indicator to predict prognosis in HL patient.
这项研究调查了新诊断霍奇金淋巴瘤（HL）患者的血清 25-羟维生素 D（25-（OH）D）缺乏及其预后价值。该研究纳入了 77 名患者，25-（OH）D 的中位水平为 44.5 nmol/L（范围为 15.5-100.9 nmol/L），其中 16 名（20.8%）被认为存在 25-（OH）D 缺乏。中位随访时间为 28 个月（范围为 4-56 个月），2 年无进展生存率（PFS）和总生存率（OS）分别为 75.3%±5.5%和 94.7%±3.0%。25-（OH）D 水平缺乏的患者 PFS 较差（P<0.001），OS 也较差（P<0.001）。多变量 Cox 分析显示，25-（OH）D 缺乏是 PFS（风险比（HR）3.323，95%CI 1.527-7.229，P=0.002）和 OS（HR 5.819，95%CI 1.322-25.622，P=0.020）的独立预后因素。接收者操作特征（ROC）曲线显示，国际预后评分（IPS）加 25-（OH）D 缺乏（IPS-D）比 IPS 在 PFS（AUC：0.735（95%CI 0.622-0.829）vs.0.701（95%CI 0.586-0.800），P=0.033）和 OS（AUC：0.864（95%CI 0.767-0.932）vs.0.825（95%CI 0.722-0.902），P=0.028）方面预测更准确。所有这些发现表明，血清 25-（OH）D 水平可能是预测 HL 患者预后的辅助指标。
